ES2549551T1 - Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas - Google Patents

Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas Download PDF

Info

Publication number
ES2549551T1
ES2549551T1 ES15152726.4T ES15152726T ES2549551T1 ES 2549551 T1 ES2549551 T1 ES 2549551T1 ES 15152726 T ES15152726 T ES 15152726T ES 2549551 T1 ES2549551 T1 ES 2549551T1
Authority
ES
Spain
Prior art keywords
stiffness
increasing bone
bone hardness
reducing fractures
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES15152726.4T
Other languages
English (en)
Other versions
ES2549551T3 (es
Inventor
Janet M Hock
Gregory A Gaich
Willard H Dere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2549551(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2549551T1 publication Critical patent/ES2549551T1/es
Application granted granted Critical
Publication of ES2549551T3 publication Critical patent/ES2549551T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

PTH(1-34) humana para su uso en un metodo para la reducción de la incidencia y/o gravedad de fractura, en un hombre con riesgo de padecer o con osteoporosis, mediante la administración de PTH(1-34) por inyección subcutánea de una dosis de menos de 1 mg/kg/dia.

Claims (1)

  1. imagen1
ES15152726.4T 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas Expired - Lifetime ES2549551T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US97151P 1998-08-19
US9974698P 1998-09-10 1998-09-10
US99746P 1998-09-10

Publications (2)

Publication Number Publication Date
ES2549551T1 true ES2549551T1 (es) 2015-10-29
ES2549551T3 ES2549551T3 (es) 2017-11-27

Family

ID=26792729

Family Applications (4)

Application Number Title Priority Date Filing Date
ES10180447.4T Expired - Lifetime ES2621653T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas
ES15152726.4T Expired - Lifetime ES2549551T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas
ES99942350T Expired - Lifetime ES2190244T3 (es) 1998-08-19 1999-08-19 Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
ES06027055T Expired - Lifetime ES2393200T3 (es) 1998-08-19 1999-08-19 hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10180447.4T Expired - Lifetime ES2621653T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES99942350T Expired - Lifetime ES2190244T3 (es) 1998-08-19 1999-08-19 Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
ES06027055T Expired - Lifetime ES2393200T3 (es) 1998-08-19 1999-08-19 hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre

Country Status (33)

Country Link
US (2) US6977077B1 (es)
EP (3) EP2907522B1 (es)
JP (5) JP2002523375A (es)
KR (1) KR100454207B1 (es)
CN (1) CN1205997C (es)
AR (1) AR033639A1 (es)
AT (1) ATE231000T1 (es)
AU (1) AU746277B2 (es)
BR (1) BR9909445A (es)
CA (1) CA2325371C (es)
CO (1) CO5130020A1 (es)
CY (2) CY1113343T1 (es)
CZ (1) CZ301017B6 (es)
DE (2) DE69904918T2 (es)
DK (4) DK2907522T3 (es)
DZ (1) DZ2873A1 (es)
EA (1) EA003362B1 (es)
ES (4) ES2621653T3 (es)
HK (3) HK1030545A1 (es)
HR (1) HRP20000755A2 (es)
HU (2) HU230697B1 (es)
ID (1) ID29039A (es)
IL (2) IL138829A0 (es)
MY (1) MY129227A (es)
NO (2) NO323984B1 (es)
NZ (1) NZ507056A (es)
PE (1) PE20001089A1 (es)
PL (1) PL201688B1 (es)
PT (4) PT1059933E (es)
TR (1) TR200003455T2 (es)
TW (1) TW576747B (es)
UA (1) UA72205C2 (es)
WO (1) WO2000010596A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP2005525312A (ja) * 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2539357A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
JP2008540522A (ja) * 2005-05-11 2008-11-20 ユニジーン・ラボラトリーズ・インコーポレーテッド 骨の形成および保存を促進するための方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
US8961947B2 (en) 2007-04-13 2015-02-24 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
WO2009072119A2 (en) * 2007-12-04 2009-06-11 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
CA2710798A1 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
KR20170089017A (ko) 2009-09-09 2017-08-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6815407B2 (ja) 2016-02-01 2021-01-20 イーライ リリー アンド カンパニー 副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
EP3576774A4 (en) * 2017-02-01 2020-10-07 The Johns Hopkins University PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
WO2021030222A1 (en) 2019-08-09 2021-02-18 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
CN1170527C (zh) * 1994-12-22 2004-10-13 阿斯特拉公司 含有甲状旁腺激素(pth)的吸入用治疗剂
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
AU752925B2 (en) * 1997-09-09 2002-10-03 F. Hoffmann-La Roche Ag Fracture healing using PTHrP analogs
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
NZ507056A (en) 2003-10-31
WO2000010596A1 (en) 2000-03-02
PT2266598T (pt) 2017-05-02
EP2907522A1 (en) 2015-08-19
EA003362B1 (ru) 2003-04-24
EP1059933A1 (en) 2000-12-20
BR9909445A (pt) 2000-12-12
HU230697B1 (hu) 2017-09-28
TR200003455T2 (tr) 2001-06-21
AU746277B2 (en) 2002-04-18
EA200001015A1 (ru) 2001-02-26
CZ20004134A3 (cs) 2001-08-15
MY129227A (en) 2007-03-30
PL201688B1 (pl) 2009-04-30
IL138829A (en) 2011-01-31
PT2907522T (pt) 2017-10-23
US20050197294A1 (en) 2005-09-08
KR100454207B1 (ko) 2004-10-26
EP2907522B1 (en) 2017-08-02
DE15152726T1 (de) 2015-12-10
ATE231000T1 (de) 2003-02-15
EP1059933B1 (en) 2003-01-15
NO20005947L (no) 2000-11-24
CN1205997C (zh) 2005-06-15
DK1769804T3 (da) 2012-10-15
CZ301017B6 (cs) 2009-10-14
CA2325371C (en) 2004-08-17
CO5130020A1 (es) 2002-02-27
ES2621653T3 (es) 2017-07-04
US7163684B2 (en) 2007-01-16
ID29039A (id) 2001-07-26
DZ2873A1 (fr) 2003-12-15
DK2907522T3 (en) 2017-10-23
DK2907522T1 (da) 2015-10-19
HK1212602A1 (zh) 2016-06-17
NO20072983L (no) 2000-11-24
US6977077B1 (en) 2005-12-20
PE20001089A1 (es) 2000-11-04
JP2011021035A (ja) 2011-02-03
ES2393200T3 (es) 2012-12-19
EP2266598A1 (en) 2010-12-29
NO20005947D0 (no) 2000-11-24
PT1059933E (pt) 2003-06-30
HUP0101594A2 (hu) 2001-11-28
JP2017190332A (ja) 2017-10-19
HU1200430D0 (hu) 2001-11-28
JP2002523375A (ja) 2002-07-30
CY1113343T1 (el) 2016-06-22
JP2014139220A (ja) 2014-07-31
IL138829A0 (en) 2001-10-31
HK1102496A1 (en) 2007-11-23
HK1030545A1 (en) 2001-05-11
PL343595A1 (en) 2001-08-27
HUP0101594A3 (en) 2002-01-28
PT1769804E (pt) 2012-11-13
JP2015028065A (ja) 2015-02-12
DE69904918T2 (de) 2003-11-13
TW576747B (en) 2004-02-21
ES2190244T3 (es) 2003-07-16
EP2266598B1 (en) 2017-02-22
CY1119552T1 (el) 2018-03-07
AR033639A1 (es) 2004-01-07
KR20010072763A (ko) 2001-07-31
UA72205C2 (uk) 2005-02-15
AU5575099A (en) 2000-03-14
NO323984B1 (no) 2007-07-30
JP6177718B2 (ja) 2017-08-09
DK2266598T3 (en) 2017-05-15
CN1308545A (zh) 2001-08-15
ES2549551T3 (es) 2017-11-27
DK1059933T3 (da) 2003-04-07
DE69904918D1 (de) 2003-02-20
CA2325371A1 (en) 2000-03-02
HRP20000755A2 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
ES2549551T1 (es) Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
EP1605842A4 (en) BONE FRACTURE FASTENING SYSTEM HAVING SUB-CHONDERAL AND ARTICULAR SURFACE SUPPORT
SE9500566L (sv) L-platta
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
EP1713410A4 (en) SYSTEM FOR STABILIZING FRACTURES OF CONVEX TUBE BONE SURFACES WITH SUBCHONDRIAL SUPPORT STRUCTURE
MXPA05004225A (es) Anticuerpos de neutralizacion contra gdf-8, y sus usos.
ES2138067T3 (es) Proceso para el tratamiento de un implante quirurgico.
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
BR9508322A (pt) Uso de quitosan e de um polissacarídeo imobilizado no mesmo processo para estimular e/ou acelerar regeneração de tecido rígido e implante destinado para integração em tecido rígido
ES2075125T3 (es) Tornillo como medio auxiliar de osteosintesis.
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
ATE148328T1 (de) Knochenchirurgische haltevorrichtung
DE69918848D1 (de) Vorderseitenplatte für lendenwirbel und positionierwerkzeug dafür
WO2004045455A3 (en) Deformable bone plates
AU5819094A (en) Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes
AU5396199A (en) Bone fixation apparatus and method
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
ATE543451T1 (de) Bioabsorbierbare, osteogenetische knochenplatte
MY137620A (en) Therapeutic treatment
BR0314362A (pt) Método para previnir ou reduzir fraturas secundárias após fratura de quadril
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
BR9810904A (pt) Tramento de diabetes com tiazolidinodiona e sulfoniluréia
EE9700068A (et) Selegiliini kasutamine epileptiliste haiguste raviks